Insight Molecular Diagnostics IMDX Institutional Ownership

Updated Oct 5, 2026

Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) was reported as a holding by 41 institutional investors in 13F filings for the quarter ended June 30, 2026.

• These investors held 50.24% of Insight Molecular Diagnostics' outstanding shares at the end of Q2 2026, down from 54.85% in Q1 2026.
• Total shares held in Insight Molecular Diagnostics fell 2.48% versus Q1 2026, while the number of holders rose 46.43% versus Q2 2025.
• Of the 41 holders, 24 added to their positions, 8 reduced their stakes and 9 left their positions unchanged in Q2 2026.
• Altogether, institutional holders owned 18.46Mn IMDX shares at the end of Q2 2026, down 468.71K from the prior quarter and up 3.29Mn from a year earlier.
• Broadwood Capital Inc held the largest position in IMDX at 12.68Mn shares as of June 30, 2026, or 34.52% of shares outstanding.
• The largest position increases in IMDX for Q2 2026 were by Broadwood Capital Inc (+753.04K shares), Family Office Research LLC (+241.58K shares), Vanguard Capital Management LLC (+198.69K shares), State Street Corp (+41.37K shares) and UBS Group AG (+30.52K shares).
• The biggest cuts to IMDX positions during Q2 2026 came from Pura Vida Investments, LLC (-462.29K shares), FNY Investment Advisers, LLC (-64.86K shares), Millennium Management LLC (-20.97K shares), XTX Topco Ltd (-19.61K shares) and Vanguard Fiduciary Trust Co (-8.02K shares).
• According to Business Quant data, the leading holders of IMDX for Q2 2026 were Broadwood Capital Inc (12.68Mn shares), AWM Investment Company, Inc. (2.84Mn shares), Vanguard Capital Management LLC (735.85K shares), Pura Vida Investments, LLC (484.85K shares), Family Office Research LLC (368.85K shares), Geode Capital Management, LLC (256.9K shares), FNY Investment Advisers, LLC (182.56K shares), Jane Street Group, LLC (157.68K shares), BlackRock, Inc. (150.52K shares) and Vanguard Fiduciary Trust Co (124.58K shares).